Vise Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vise Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$181K	Buy	+21,700	New	+$204K	﹤0.01%	1994

Other funds holding BCRX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

Vise Technologies's BCRX Position: Q3 2026 in Review

Vise Technologies opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2026: 21,700 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #1994 among its holdings.

61 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

Vise Technologies held 21,700 shares of BioCryst Pharmaceuticals worth $181K as of Q3 2026.
BioCryst Pharmaceuticals was a new Vise Technologies position in Q3 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Vise Technologies's portfolio in Q3 2026, its #1994 holding.
61 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Vise Technologies's 13F filing for Q3 2026, filed 29 Oct 2026.